STOCK TITAN

Auna Q3 net income falls 54% to S/24 million

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Auna S.A. (AUNA) reported third-quarter 2026 revenue of S/1,325 million, up 19% as reported and 10% on an FX-neutral basis. Adjusted EBITDA was S/231 million, flat as reported and down 5% FX-neutral; net income was S/24 million, compared with S/53 million a year earlier. Mexico segment Adjusted EBITDA rose 5% in local currency, while Peru declined 6% and Colombia declined 30%.

For the nine months ended September 30, 2026, operating cash flow rose 62% to S/713 million and free cash flow rose 95% to S/626 million. Net debt was S/3,133 million and leverage was 3.5x at September 30, 2026, compared with 3.6x at September 30, 2025 and December 31, 2025.

Auna reaffirmed full-year 2026 revenue growth guidance of 10% to 14% FX-neutral and capital expenditures of approximately 4% of consolidated revenues. Its Adjusted EBITDA outlook is now broadly stable or slightly down year over year, versus prior guidance of 10% to 14% FX-neutral growth. The Centro Ambulatorio Trecca project entered construction on November 3 after conditions were fulfilled; it is structured as a 20-year concession, with operations currently expected by late 2028.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointRevenue increased 19% as reported in 3Q26, including 10% FX-neutral growth.
  • Moderate pointNine-month operating cash flow rose 62% to S/713 million.
  • Moderate pointNine-month free cash flow rose 95% to S/626 million.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Full-year Adjusted EBITDA outlook shifted from 10% to 14% FX-neutral growth to broadly stable or slightly down year over year.
  • Moderate pointThird-quarter net income fell 54% to S/24 million year over year.
  • Moderate pointThird-quarter Adjusted EBITDA declined 5% FX-neutral.

Filing Explained

After the quarter closed, Auna terminated a Colombian oncology risk-sharing contract covering about 500,000 lives and representing about 4% of Colombia revenue, after treatment costs exceeded contractual assumptions, and says the termination is intended to limit further exposure while recovery options remain under legal review.

Revenue S/1,325 million; up 19% as reported and 10% FX-neutral Third quarter 2026
Adjusted EBITDA S/231 million; flat as reported and down 5% FX-neutral Third quarter 2026
Net income S/24 million Third quarter 2026, compared with S/53 million in 3Q25
Net cash from operating activities S/713 million; up 62% year over year Nine months ended September 30, 2026
Free cash flow S/626 million; up 95% year over year Nine months ended September 30, 2026
Leverage ratio 3.5x At September 30, 2026; compared with 3.6x at September 30, 2025 and December 31, 2025
Revenue growth guidance 10% to 14% FX-neutral growth Full-year 2026 guidance, reaffirmed
Capital expenditures guidance Approximately 4% of consolidated revenues Full-year 2026 guidance
FX-neutral financial
"10% on an FX-neutral basis"
fx-neutral means presenting financial figures with the effects of changes in currency exchange rates removed, so reported revenue or growth reflects only the company’s underlying operations rather than shifts in foreign-money values. Investors use fx-neutral numbers to compare performance across periods and regions more fairly — like comparing a car’s fuel efficiency after removing differences caused by driving on hills versus flat roads, isolating true performance.
Adjusted EBITDA financial
"Adjusted EBITDA was S/231 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Free Cash Flow financial
"Free Cash Flow increased 95% to S/626 million"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
Leverage Ratio financial
"Leverage Ratio improved to 3.5x"
Leverage ratio measures how much a company relies on borrowed money compared with its own funds or assets, typically expressed as debt relative to equity or total assets. Like a homeowner with a mortgage, higher leverage can amplify returns when business is strong but also raises the chance of big losses or default if revenue falls, so investors use it to judge financial risk and resilience.
Public-Private Partnership technical
"Auna’s Public-Private Partnership (PPP) with EsSalud"
A public-private partnership is a collaborative arrangement where government entities and private companies work together to fund, build, and operate projects or services that benefit the public, such as roads, schools, or hospitals. For investors, these partnerships can create opportunities to invest in infrastructure and services that have long-term stability and potential for steady returns, as they combine public support with private sector efficiency.
non-IFRS financial measures financial
"This release includes “non-IFRS financial measures”"
Non-IFRS financial measures are company-reported numbers that modify or exclude items from standard accounting results so management can highlight what it sees as underlying business performance—common examples are adjusted EBITDA or adjusted earnings per share. They matter to investors because they can make trends clearer by removing unusual or noncash items, like cleaning lens smudges off a camera, but they require scrutiny since companies decide what to exclude and comparisons across firms may not be uniform.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were AUNA's third-quarter 2026 revenue and Adjusted EBITDA?

AUNA reported S/1,325 million of revenue and S/231 million of Adjusted EBITDA in 3Q26. Revenue was up 19% as reported and 10% FX-neutral; Adjusted EBITDA was flat as reported and down 5% FX-neutral.

What is AUNA's full-year 2026 guidance?

AUNA reaffirmed full-year 2026 revenue growth guidance of 10% to 14% on an FX-neutral basis and capital expenditures of approximately 4% of consolidated revenues. It revised its Adjusted EBITDA outlook to broadly stable or slightly down year over year, versus prior guidance of 10% to 14% FX-neutral growth.

When is AUNA's Trecca facility expected to open, and what capacity will it add?

The Centro Ambulatorio Trecca facility is currently expected to begin operations by late 2028. The 23-story facility is projected to increase EsSalud healthcare capacity in metropolitan Lima by approximately 20% and support more than three million patient visits annually. Construction expenditures will be reimbursed through progress certificates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

Commission File Number: 001-41982

 

Auna S.A.

(Exact name of registrant as specified in its charter)

 

‎ 6, rue Jean Monnet

L-2180 Luxembourg

Grand Duchy of Luxembourg

‎+51 1-205-3500‎

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

X

  Form 40-F  

 

 
 

TABLE OF CONTENTS

 

EXHIBIT  
99.1 Press release dated November 17, 2026 — Auna announces 3Q26 Financial Results
99.2 Condensed Consolidated Interim Financial Statements as of and for the nine months ended September 30, 2026

 

 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Auna S.A.
   
   
  By: /s/ Gisele Remy
    Name: Gisele Remy
    Title: Chief Financial Officer

Date: November 17, 2026

 

 

 

Exhibit 99.1

 

Auna Announces 3Q26 Financial Results

 

Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026;

Mexico Returns to Year-over-Year Adjusted EBITDA Growth;

Profitability Pressured by Specific Headwinds in Colombia and Peru

Leverage Improves to 3.5x

 

 

Luxembourg, November 17, 2026 – Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today unaudited financial results for the third quarter ended September 30, 2026 (“Third quarter 2026” or “3Q26”). Financial results are expressed in Peruvian Soles (“S/” or “PEN” or “Soles”) and are presented in accordance with International Financial Reporting Standards (“IFRS”), unless otherwise noted.

 

3Q’26 Consolidated Highlights

 

●Revenue increased 10% YoY FXN and 19% YoY as reported to S/1,325 million, with sequential growth of 3% FXN and 7% as reported

 

●Adjusted EBITDA was S/231 million, decreasing 4.6% FXN while remaining flat as reported. Sequentially, Adjusted EBITDA was stable FXN and increased 2% as reported

 

●Mexico Segment Adjusted EBITDA increased 5% YoY in local currency, marking its first year-over-year growth in 2026

 

●Adjusted EBITDA Margin of 17.5%, compared to 18.4% in 2Q26

 

●Year to date Net Cash from Operating Activities increased 62% YoY to S/713 million, while Free Cash Flow increased 95% to S/626 million

 

●Leverage Ratio improved to 3.5x

 

●Oncology MLR remained stable at 50.7%

 

●Number of surgeries increased 12% YoY to 23,932

 

●Number of days hospitalized increased 6% YoY to 144,041

 

●Number of chemotherapy and radiotherapy sessions increased 7% YoY

 

1 

 

Recent Developments

 

Centro Ambulatorio Trecca Public-Private Partnership Enters Construction Phase

 

On November 3, 2026, Centro Ambulatorio Trecca formally entered its construction phase following the fulfillment of all conditions precedent under Auna’s Public-Private Partnership (PPP) with EsSalud. This milestone keeps the project on schedule and represents an important step in expanding access to quality healthcare in Peru. The commencement was marked by an event attended by national authorities, including the President of the Republic of Peru, Keiko Fujimori, as well as EsSalud representatives and Auna’s leadership.

 

Structured as a 20-year, capital-light concession ring-fenced at the project level, construction expenditures will be reimbursed through progress certificates. The 23-story facility will provide Auna with access to a largely untapped segment of Peru’s healthcare market serving approximately six million EsSalud-insured residents in Lima. Once operational, currently expected by late 2028, the facility is projected to increase EsSalud’s healthcare capacity in metropolitan Lima by approximately 20% and support more than three million patient visits annually. Operations will be supported by monthly EsSalud payments based on contractually established minimum service volumes, providing long-term revenue visibility.

 

 

Full-Year 2026 Guidance Update

 

As announced on October 22, 2026, Auna reaffirms its full-year revenue guidance within the previously announced range of 10% to 14% FX-neutral growth and capital expenditures guidance of approximately 4% of consolidated revenues.

 

Auna revised its full-year 2026 Adjusted EBITDA outlook, reflecting higher-than-anticipated operating costs in Colombia, including adverse medical-costs under a specific oncology risk-sharing contract and regulatory price caps on certain high-cost oncology medications. The Company now expects full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year, compared to its previous guidance of 10% to 14% FX-neutral growth.

 

 

Message from Auna’s Executive Chairman and President

 

The third quarter of 2026 reflected continued strong commercial momentum across our markets, with revenue increasing 10% on an FX-neutral basis. Adjusted EBITDA declined 5% FX-neutral, primarily reflecting profitability pressures in Colombia and Peru, partially offset by improving performance in Mexico. The quarter marked an important milestone

 

2 

 

in Mexico’s operational recovery, with Segment Adjusted EBITDA returning to year-over-year growth, while continued strong cash generation supported further deleveraging.

 

In Peru, our resilient integrated model produced revenue growth of 6% year-over-year. The Peru Healthcare network benefited from strong surgical volumes, up 21%, alongside a greater focus on high-complexity procedures. At Oncosalud, we prioritized and grew higher-retention B2B accounts, including two new agreements to onboard 4,000 members. Adjusted EBITDA was impacted by penalties arising from the reconciliation of prior years’ receivables, as well as higher pharmacy and clinical payroll costs associated with increased patient volumes.

 

In Mexico, we are seeing tangible results from the commercial and operational initiatives implemented earlier this year. Segment Adjusted EBITDA increased 5% year-over-year in local currency, marking its first quarter of year-over-year growth in 2026. This improvement was driven by strong performance in the Monterrey Healthcare network, supported by higher surgical and oncology volumes and improved capacity utilization, which more than offset softer results at Auna Seguros following changes in VAT deductibility. With double-digit oncology revenue growth and improving operating efficiency, we remain focused on further improving this recovery and translating higher utilization into stronger profitability.

 

In Colombia, revenue increased 12% in local currency, supported by increased hospital capacity in Montería and continued growth in our PGP arrangements. However, Segment Adjusted EBITDA declined 30% in local currency, primarily reflecting two items: first, extraordinary adverse medical-costs under a specific oncology risk-sharing contract, where utilization and treatment costs significantly exceeded contractual assumptions; and second, regulatory price caps on certain high-cost oncology medications. These were further compounded by higher personnel costs across the segment. We have terminated the risk sharing contract to limit further exposure as it represented approximately 4% of Colombia´s revenues and have engaged legal counsel to review all recovery options under the contract. We remain focused on strengthening contract economics, improving operating efficiency, and restoring profitability.

 

Consolidated cash flow generation remained a significant strength of our platform. Year-to-date Net Cash from Operating activities increased 62% year-over-year to S/713 million, while Free Cash Flow increased 95% to S/626 million, supported by disciplined working capital management, and lower tax payments. This performance contributed to a reduction in net debt and an improvement in our leverage ratio towards 3.5x, bringing it closer to our medium-term target of below 3.0x.

 

We reached an important milestone with the commencement of construction of Centro Ambulatorio Trecca in Lima. This capital-light public-private partnership will significantly expand our addressable market and provide long-term contractual revenue visibility, reinforcing our strategy of developing capital-efficient growth opportunities.

 

3 

 

Looking ahead, as discussed at our recent 2026 Investor Day, we remain confident in the underlying growth trajectory of our business. We reaffirm our full-year 2026 revenue guidance, expecting FX-neutral growth within our 10% to 14% range. However, reflecting the profitability pressures discussed above, particularly in Colombia, we now expect full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year. Capital expenditures guidance remains unchanged at approximately 4% of revenues.

 

We remain focused on accelerating growth in Mexico, restoring profitability in Colombia, improving earnings quality and operating efficiency in Peru, and translating our commercial momentum into even stronger cash generation and growing, sustainable returns for our shareholders. We are committed to disciplined execution, strengthening our financial performance, and creating long-term shareholder value.

 

 

Overview of 3Q26 Consolidated Results

 

Revenues increased 10% YoY FXN and 19% as reported to S/1,325 million, with growth measured in local currency (“LC”) across all three markets:  16% in Mexico, 6% in Peru, and 12% in Colombia. In Mexico, growth was driven by higher surgery and oncology volumes at the Monterrey Healthcare network, partially offset by softer performance in Auna Seguros. In Peru, revenue growth was supported by increased healthcare activity, particularly high-complexity procedures and continued growth in Oncosalud’s B2B business. In Colombia, revenue growth benefited from expanded hospital capacity.

 

Adjusted EBITDA decreased 5% YoY FXN and remained flat as reported at S/231 million, with an Adjusted EBITDA margin of 17.5%. In LC, Segment Adjusted EBITDA increased 5% in Mexico, while declining 6% in Peru and 30% in Colombia. Mexico recorded its first quarter of year-over-year Segment Adjusted EBITDA growth in 2026, driven by improving profitability in the Monterrey Healthcare network, partially offset by softer results at Auna Seguros. In Peru, profitability was impacted by penalties related to the reconciliation of prior years’ receivables, as well as higher MLR from a larger mix of healthcare plans and the ramp up of new B2B oncology plans. In Colombia, profitability was primarily affected by adverse medical-costs under a specific oncology risk-sharing contract, which Auna has since terminated and regulatory price caps on certain high-cost oncology medications.

 

Reported results were impacted by foreign exchange fluctuations, including a 3% appreciation of the Mexican Peso (MXN) and a 20% appreciation of the Colombian Peso (COP) both against the Peruvian Sol (PEN).

 

4 

 

Net finance costs were S/112 million in 3Q26, compared to S/72 million in 3Q25. The increase primarily reflected a S/40 million non-cash FX gain recognized in 3Q25 that did not recur in 3Q26, due to Auna resetting its USD/PEN call spread to 3.40-3.80 in Q425.  The remainder of the change was due to an increase in Finance costs consisting of (i) a S/6 million non-cash finance expense related to the future purchase obligation for IMAT Oncomedica in 3Q26 versus S/1 million in 3Q25; and (ii) Interest expense and other costs of S/114 in 3Q26 versus S/115 in 3Q25, and partially offset by Finance income of S/7 million in 3Q26 versus S/4 million in 3Q25. Excluding non-cash effects, Net finance costs were S/107 million in 3Q26, compared to S/110 million in 3Q25.

 

Net Income was S/24 million in 3Q26, compared to S/53 million in 3Q25 primarily reflecting the absence of the significant S/40 million non-cash FX gain recorded in the prior-year period, partially offset by S/20 million in lower income tax expenses. On a per-share basis, Net Income was S/0.27, based on a weighted average of 74,235,734 basic and diluted shares.

 

Adjusted Net Income was S/35 million in 3Q26, compared to S/58 million in 3Q25, primarily reflecting the non-cash FX effects described above, partially offset by lower income tax expenses. On a per-share basis, Adjusted Net Income was S/0.41, based on a weighted average of 74,235,734 basic and diluted shares.

 

Business performance

 

HEALTHCARE SERVICES MEXICO

(Explanations of variances are in local currency unless expressed otherwise)

 

Auna’s Healthcare Services and Auna Seguros’ operations in Mexico accounted for 24% of consolidated revenues and 36% of consolidated Adjusted EBITDA in the quarter.

 

 Healthcare Services Mexico

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

               Δ 3Q'26 vs 3Q'25  Δ 3Q'26 vs 2Q'26  Δ YTD 26 vs YTD 25
Healthcare Services Mexico
Key Operating Metrics
     3Q'26 (USD)  3Q'26  YTD 26  As
Reported
  L.C.  As
Reported
  L.C.  As
Reported
  L.C.
Beds   #         708    708    0%        0%        0% 
Surgeries            6    16    12%        12%        7% 
Emergency treatments   #(000)        8    24    9%        1%        1% 
Radiotherapy & Chemotherapy   #(000)        5    14    34%        -1%        62% 
Total number of days hospitalized   #(000)        27    77    5%        6%        2% 
Operating capacity utilization   %         50.5%   49.0%   2.9 p.p.         0.6 p.p.         1.3 p.p.    
Total capacity utilization   %         41.1%   39.9%   2.0 p.p.         2.0 p.p.         0.7 p.p.    
Key Financial Metrics                                                
Segment Revenue        92    316    895    20%   16%   5%   6%   15%  9%
Segment Adjusted EBITDA        24    83    234    8%   5%   7%   8%   -4%  -9%
Segment Adjusted EBITDA margin   %         26.3%   26.2%   -2.7 p.p.         0.4 p.p.         -5.2 p.p.    

 

5 

 

Segment revenue in Mexico increased 16% YoY in LC, driven by an 18% increase in the Monterrey Healthcare Services network. Sequentially, Segment revenue grew 6% compared to 2Q26, with Healthcare Services remaining the primary growth driver. Growth was supported by higher volumes across surgeries, intensive care, and chemotherapy sessions, reflecting the continued benefits of operational initiatives implemented in previous quarters.

 

Auna continued to benefit from improved tier classifications with two key payors at Doctors Hospital (“DH”), its largest healthcare facility, where patient volumes associated with these payors increased 25% and related revenues surged 63% YoY. Total surgery revenues at DH also increased 22% YoY. Additionally, the renewal of the ISSSTELEON B2B agreement at OCA, which included improved pricing that reflects the complexity of services provided, contributed to a 16% YoY increase in related revenues. Private out-of-pocket revenues across the network increased 11% YoY, while patient volumes from surgical and hemodynamic packages tripled over the same period.

 

In oncology, radiotherapy and chemotherapy revenues increased 73% YoY and 5% QoQ, representing 10% of Monterrey’s network revenues in 3Q26, up from 7% in 3Q25.

 

Operationally, approximately 52% of the network’s productive physicians increased their service volumes during the quarter, while nursing staffing coverage and retention improved compared to 2025. The network also strengthened physician onboarding criteria, with a greater focus on productivity. During the quarter, Auna onboarded 28 physicians who actively treated patients for at least two months and met minimum billing thresholds, primarily in specialties including traumatology, cardiology, and general medicine.

 

Higher volumes across surgeries, emergency treatments, hospitalizations, and intensive care contributed to total capacity utilization of 41.1%, an increase of 2.0 percentage points both YoY and QoQ.

 

Segment Adjusted EBITDA increased 5% YoY in local currency, with an Adjusted EBITDA margin of 26.3%. This marked the segment’s first quarter of year-over-year Adjusted EBITDA growth in 2026, reflecting continued progress in its operational recovery. Within the segment, the Monterrey Healthcare network’s Adjusted EBITDA increased 10% YoY, reaching a margin of 28%, despite higher pharmacy costs related to changes in service mix, investments in talent retention, and the implementation of a new mandatory medical insurance benefit for employees.

 

Sequentially, Segment Adjusted EBITDA increased 8% in local currency, supported by 9% growth in the Monterrey Healthcare network’s Adjusted EBITDA and a 0.7 percentage point improvement in its margin compared to 2Q26. These results provide further evidence of the ongoing recovery in the network’s operating profitability.

 

Conversely, Auna Seguros revenues remained flat YoY, while Adjusted EBITDA was negatively impacted by a new 2026 sector-wide regulation restricting VAT deductibility for insurance products.

 

6 

 

PERU OPERATIONS: HEALTHCARE SERVICES PERU AND ONCOSALUD PERU

 

Auna’s Healthcare Services and Oncosalud Peru accounted for 39% of consolidated revenues and 45% of consolidated Adjusted EBITDA in the quarter.

 

Peru Consolidated (Healthcare Services Peru and Oncosalud Peru)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

Healthcare Services Peru and
Oncosalud Peru
Key Financial Metrics
     3Q'26 (USD)  3Q'26  YTD 26  Δ 3Q'26 vs 3Q'25  Δ 3Q'26 vs 2Q'26  Δ YTD 26 vs YTD 25
Consolidated Revenue        150    516    1,528    6%   1%  7%
Healthcare Services Peru        89    307    885    10%   4%  9%
Oncosalud Peru        94    323    954    10%   2%  11%
Holding and Eliminations (*)             (114)   (310)   35%   13%  24%
Consolidated Peru Adjusted EBITDA        30    104    304    -6%   3%  -3%
Healthcare Services Peru        11    37    102    -16%   6%  -15%
Oncosalud Peru        20    68    202    0%   1%  4%
Consolidated Peru Adj. EBITDA margin   %         20.2%   19.9%   -2.6 p.p.    0.4 p.p.   -2.1 p.p.
Healthcare Services Peru             11.9%   11.5%   -3.8 p.p.    0.2 p.p.   -3.2 p.p.
Oncosalud Peru             20.9%   21.2%   -2.0 p.p.    -0.1 p.p.   -1.4 p.p.

 

(*) Relates to intersegment revenue elimination.

 

 

Healthcare Services Peru

Healthcare Services Peru
Key Operating Metrics
     3Q'26 (USD)  3Q'26  YTD 26  Δ 3Q'26 vs 3Q'25  Δ 3Q'26 vs 2Q'26  Δ YTD 26 vs YTD 25
Beds   #         389    389    1%   0%  1%
Surgeries   #(000)        6    18    21%   10%  11%
Emergency treatments   #(000)        54    151    10%   4%  12%
Chemotherapies & Radiotherapies   #(000)        14    40    18%   6%  6%
Total number of days hospitalized   #(000)        32    94    6%   2%  8%
Operating capacity utilization   %         92.6%   91.4%   4.9 p.p.    0.6 p.p.   7.1 p.p.
Total capacity utilization   %         89.2%   88.1%   3.9 p.p.    0.6 p.p.   6.0 p.p.
Key Financial Metrics                              
Revenue        89    307    885    10%   4%  9%
External revenues        60    207    616    3%   0%  5%
Intercompany revenue        29    100    269    29%   13%  21%
Segment Adjusted EBITDA        11    37    102    -16%   6%  -15%
Segment Adjusted EBITDA margin   %         11.9%   11.5%   -3.8 p.p.    0.2 p.p.   -3.2 p.p.

 

7 

 

Oncosalud Peru

 

Oncosalud Peru
Key Operating Metrics
     3Q'26 (USD)  3Q'26  YTD 26  Δ 3Q'26 vs 3Q'25  Δ 3Q'26 vs 2Q'26  Δ YTD 26 vs YTD 25
Plan memberships   #(000)        1,442    1,442    3%   -2%  3%
Oncological Plans   #(000)        973    973    -2%   -3%  -2%
Average monthly revenue per plan membership        18.98    65.15    64.02    5%   3%  5%
Preventive check-ups   #(000)        25    82    -14%   -4%  -13%
Patients treated   #(000)        56    154    34%   10%  28%
MLR   %              58.7%            4.2 p.p.
Oncological Plans   %              50.7%            1.4 p.p.
Key Financial  Metrics                              
Revenue        94    323    954    10%   2%  11%
External revenues        90    308    912    8%   1%  9%
Intercompany revenue        4    14    41    96%   9%  53%
Segment Adjusted EBITDA        20    68    202    0%   1%  4%
Segment Adjusted EBITDA margin   %         20.9%   21.2%   -2.0 p.p.    -0.1 p.p.   -1.4 p.p.

 

Total revenue in Peru increased 6% YoY to S/516 million in 3Q26. Healthcare Services Peru revenue increased 10% YoY, supported by higher surgery, emergency, and oncology volumes. Emergency treatments increased 10% YoY, benefiting from commercial initiatives with corporate accounts, while surgeries grew 21%, alongside a greater focus on high-complexity procedures and higher average revenue per surgery. Total bed capacity increased 1% YoY to 389 beds, including the addition of four ICU beds. Hospitalization days increased 6% YoY, while total capacity utilization reached 89.2%, an improvement of 3.9 percentage points.

 

Oncosalud Peru revenue increased 10% YoY, supported by annual pricing adjustments and 3% growth in total plan memberships. Auna continued to prioritize B2B accounts with stronger retention characteristics, adding two new agreements to onboard 4,000 members beginning in 4Q26.

 

Preventive check-ups, as planned, declined 14% YoY, reflecting a more targeted approach to screening members at higher risk of developing breast, colorectal, cervical, or prostate cancers. Meanwhile, patients treated increased 34% YoY, driven by increased healthcare plan memberships and the initial utilization among newly onboarded B2B members.

 

Oncosalud's overall MLR increased 4.2 percentage points year-to-date to 58.7%, while the Oncology MLR increased 1.4 percentage points to 50.7%. The overall MLR increase reflects a greater mix of healthcare plans while the Oncology MLR increase reflects the initial higher average MLR from newly onboarded B2B accounts.

 

Consolidated Peru Adjusted EBITDA decreased 6% YoY to S/104 million in 3Q26, with an Adjusted EBITDA margin of 20.2%, compared to 22.8% in 3Q25. Profitability was impacted by higher pharmacy costs associated with the onboarding of new B2B accounts and

 

8 

 

increased clinical and nursing payroll expenses to support growing hospitalization and emergency volumes while maintaining capacity and quality standards. Results were also affected by penalties related to billing matters arising from the reconciliation of prior years' receivables. Excluding impacts related to billing matters, EBITDA growth in the quarter would have been broadly stable YoY.

 

 

HEALTHCARE SERVICES COLOMBIA

(Explanations of variances are in local currency unless expressed otherwise)

 

Auna’s Healthcare services operations in Colombia accounted for 37% of consolidated revenues and 19% of consolidated Adjusted EBITDA in the quarter.

 

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

 

             Δ 3Q'26 vs 3Q'25  Δ 3Q'26 vs 2Q'26  Δ YTD 26 vs YTD 25
Healthcare Services Colombia
Key Operating Metrics
     3Q'26 (USD)  3Q'26  YTD 26  As
Reported
  L.C.  As
Reported
  L.C.  As
Reported
  L.C.
Beds             1,155    1,155    2%        2%        2% 
Protected Lives             3,209    3,209    6%        2%        6% 
Surgeries             12    34    7%        8%        5% 
Emergency treatments             39    116    6%        3%        5% 
Chemotherapies & Radiotherapies   #(000)        37    109    0%        4%        1%   
Total number of days hospitalized   #(000)        85    248    6%        5%        4%   
Operating capacity utilization   %         88.8%   86.8%   2.7 p.p         0.0 p.p         0.7 p.p    
Total capacity utilization   %         80.3%   78.5%   3.3 p.p         1.1 p.p         1.8 p.p    
Key Financial Metrics                                                
Revenue        144    494    1,321    34%   12%   16%   4%   25%  13%
Segment Adjusted EBITDA        13    43    145    -16%   -30%   -22%   -30%   -4%  -13%
Segment Adjusted EBITDA margin   %         8.8%   10.9%   -5.1 p.p         -4.3 p.p         -3.3 p.p.    

 

Segment revenue in Colombia increased 12% YoY in local currency, supported by a 6% increase in protected lives, 7% growth in surgeries, and 6% increases in both emergency treatments and hospitalization days. Chemotherapy and radiotherapy volumes remained stable YoY and increased 4% QoQ.

 

Operating performance benefited from expanded capacity at IMAT Oncomedica in Montería, capturing growing demand for high-complexity care. During 3Q26, the hospital reactivated 18 adult ICU beds and added 24 hospitalization beds.

 

Auna continued diversifying its payor base to reduce exposure to government-intervened payors. Revenues from intervened payors represented 15% of Colombia's segment revenues in 3Q26, compared to 16% in 3Q25. Private payor revenues increased 22% YoY, accounting for 18% of segment revenues.

 

9 

 

PGP contracts in Antioquia, covering cardiovascular, ambulatory, and oncology services, accounted for 23% of Colombia's segment revenues, compared to 18% in 3Q25. These risk-sharing arrangements covered approximately 3.2 million lives at quarter-end, an increase of 6% YoY, and deliver more engagement with payors and their populations and greater cash flow predictability for Auna.

 

After the close of the quarter, the Company terminated an oncology risk-sharing contract that started in 2025 covering approximately 500,000 lives and represented approximately 4% of Colombia’s revenues, following a significantly higher incidence of advanced-stage cancers than anticipated under the contractual assumptions agreed with the payor.

 

Revenues in Montería and Barranquilla increased 15% and 10% YoY, respectively, and together represented 47% of segment revenues. Total capacity utilization reached 80.3%, an increase of 3.3p.p. YoY, returning to levels observed in 2024, before the intervention of Nueva EPS.

 

Segment Adjusted EBITDA decreased 30% YoY in local currency, with an Adjusted EBITDA margin of 8.8%, compared to 13.9% in 3Q25. Margins were affected by government-imposed price caps on certain high-cost oncology medications impacting the quarter only partially since mid-August, as well as initial operating costs associated with the capacity expansion in Montería. Additional payroll pressures reflected mandatory wage increases and the statutory reduction in the standard workweek, which resulted in higher overtime expenses.

 

The decline was also driven by adverse medical costs related to the abovementioned oncology risk-sharing contract, where an unexpectedly high incidence of advanced-stage cancer cases among the covered population resulted in treatment costs exceeding the contractual assumptions. The contract was terminated after the close of the quarter to limit further exposure and protect future profitability.

 

10 

 

Balance Sheet & Cash Flow

 

Consolidated Debt

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   Sep-26            Δ Sep-26 vs
   (USD)  Sep-26  Dec-25  Sep-25  Sep-25  Dec-25
(+) Loans and borrowings   1,049    3,600    3,533    3,526    2%   2%
Short term debt   135    465    316    658    -29%   47%
Long term debt   913    3,136    3,216    2,868    9%   -2%
(+) Lease Liabilities   43    146    124    129    13%   18%
Gross Debt   1,091    3,746    3,656    3,655    3%   2%
(-) Cash and cash equivalents / marketable securities   179    614    335    226    172%   83%
Net Debt   913    3,133    3,321    3,429    -8.6%   -5.7%
Leverage Ratio        3.5x   3.6x   3.6x   -0.1x   -0.1x

 

Gross Debt at the close of 3Q26 increased 2%, or S/90 million, versus 4Q25, to S/3,746 million. This increase was driven mainly by non-cash FX effects rather than an increase in underlying debt. The net changes reflect: (i) a negative non-cash effect of S/97 million associated with the depreciation of the PEN against the COP, the USD and the MXN of 16%, 2% and 2%, respectively; and (ii) higher accrued interest of S/46 million related to the Term Loan maturing 2030 and 2032 Senior Secured Notes. These effects were partially offset by (iii) a S/52 million reduction in short-term debt.

 

Leverage Ratio improved to 3.5x at the end of 3Q26. Compared to 3Q25 this improvement reflects an increase in cash position at the end of the period, partially offset by lower Adjusted LTM EBITDA and slightly higher gross debt driven by the aforementioned non-cash FX effects. On a sequential basis, the ratio also improved due to the increase in cash. Auna remains committed to a medium-term leverage target of below 3.0x.

 

11 

 

Consolidated Debt Amortization Profile

(Figures in millions of Soles, unless expressed otherwise)

 

   Total  Leases  Y1  Y2  Y3  Y4  Y5  Y6+
Loans and Borrowings   3,600         465    270    350    760    463    1,292 
Financial Leases   53         16    10    8    12    3    4 
Operating Leases   93    93                               
Gross Debt   3,746    93    481    280    358    772    466    1,296 

 

As of 3Q26. Excludes interest. Reflects figures post-refinancing. Y1 = October 2026 to September 2027, Y2 = October 2027 to September 2028, Y3 = October 2028 to September 2029, Y4 = October 2029 to September 2030, Y5 = October 2030 to September 2031, and Y6+ = October 2031 to September 2035.

 

Cashflow and Cash Conversion Cycle

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

Cashflow 

   YTD 26 (USD)  YTD 26  YTD 25  Δ YTD 26 vs YTD 25
Net cash from operating activities   208    713    440    62%
Net cash used in investing activities   (25)   (86)   (119)   -27%
Net cash used in financing activities   (106)   (363)   (336)   8%
Cash and cash equivalents at the end of the period   179    614    226    172%

 

Cash Conversion Cycle 

   LTM Sep-25  LTM Jun-26  LTM Sep-26
Days Sales Outstanding   91    89    88 
Days Inventory Outstanding   42    41    39 
Days Payable Outstanding   142    141    142 
Cash Conversion Cycle   -9    -10    -15 

*Measured on an average basis according to last twelve months results.

 

Net cash from operating activities was S/713 million for the nine months ended September 30, 2026 versus S/440 million in the nine months ended September 30, 2025, and included a S/172 million increase in cash generated from operating activities, mainly related to a reduction in accounts receivable days and an improvement in collections in Peru and Mexico, as well as stable collections in Colombia, and to S/101 million in lower tax payments, primarily reflecting more efficient management of tax returns in Colombia, including the timely recovery of tax balances owed to Auna.  

 

12 

 

Net cash used in investing activities for the nine months ended September 30, 2026 was S/86 million, a decrease of 27% YoY, or S/33 million versus the comparable period last year. In YTD 2026 organic maintenance CapEx was S/111 million and included (i) S/71 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations, and (iii) a S/2 million payment to the Opción Oncología doctors for the brand acquisition. Additional investing cash flows included (iv) S/ 29 million cash inflow from Auna Seguros portfolio rebalancing, partially offset by (v) S/ 6 million earnout payment to IMAT Oncomedica shareholders.

 

In the nine months ended September 30, 2025, investing activities included: S/113 million in organic maintenance CapEx, including (i) S/66 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations; and (iii) an S/8 million payment to the Opción Oncología doctors for the brand acquisition. Other cash from investing activities included (iv) S/5 million in cash and cash equivalent inflows from Auna Seguros portfolio rebalancing of investments toward liquid securities, (v) a S/15 million payment to former OCA shareholders for holdback obligations, and (vi) a S/6 million earnout payment to IMAT Oncomedica shareholders.

 

Net cash used in financing activities was S/363 million, an increase of 8% or S/27 million, for the nine months ended September 30, 2026 versus the comparable period last year. Cash used in financing activities during the period included: (i) S/228 million in interest payments and hedge premium payments, (ii) S/34 million in interest payments for working capital facilities, and (iii) a S/101 million decrease in working capital borrowings. For the comparable nine months ended September 30, 2025, cash used in financing included: (i) S/247 million in interest and hedge premium payments, (ii) S/50 million in interest payments for working capital facilities, and (iii) a S/39 million decrease in working capital borrowings.

 

 

About AUNA

 

Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2026, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,361 beds, and 1.4 million healthcare plans.

 

For more information visit www.aunainvestors.com

 

13 

 

Conference Call Details

 

When: 8:00 a.m. Eastern time, November 18, 2026

Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.

Dial-in: +1 833-461-5787 (U.S. domestic), +1 585-542-9983 (International)
International Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers

Meeting ID: 489 711 788 (Passcode)

Webcast: click here

 

Definitions and Concepts

 

Figures in US dollars (US$ or USD) for 3Q26 are presented for indicative purposes and were calculated using an FX rate of US$1= S/3.4330. All comparisons in this announcement are year-over-year (“YoY”), unless otherwise noted; additionally, results are presented in an FX neutral basis (“FXN”) for consolidated revenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted EBITDA, as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or “FX,” volatility between the comparison periods.

 

Financial results are preliminary and subject to year-end audit.

 

Use of Non-IFRS Financial Measures

 

This release includes “non-IFRS financial measures”, including: EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted LTM EBITDA, Segment EBITDA, Segment EBITDA Margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Consolidated Peru Adjusted EBITDA, Consolidated Peru Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Basic and Diluted EPS, Leverage Ratio, Free Cash Flow, and FX Neutral because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

 

In addition, management and our board of directors use these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our core operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth of our business. These are not measurements of operating performance under IFRS and have limitations as analytical tools. You should not consider such measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations of EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, FX Neutral and Leverage Ratio may be different from the calculations used by

 

14 

 

other companies for similarly titled measures, including our competitors, and therefore may not be comparable to those of other companies.

 

EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board of directors to assess our financial performance.

 

EBITDA Margin: is calculated as EBITDA divided by total revenue from contracts with customers.

 

Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

 

Adjusted EBITDA Margin: is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.

 

Adjusted Last Twelve Month (“LTM”) EBITDA: is calculated by adding the last four quarters beginning with the corresponding period.

 

Segment EBITDA: is calculated as segment profit before tax plus net finance cost and depreciation and amortization.

 

Segment EBITDA Margin: is calculated as segment EBITDA divided by total segment revenue from contracts with customers.

 

Segment Adjusted EBITDA: is calculated as segment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

 

Segment Adjusted EBITDA Margin: is calculated as segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.

 

15 

 

Segment Adjusted EBITDA Margin

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   3Q'26         Δ 3Q'26 vs  Δ YTD 26 vs
   (USD)  3Q'26  YTD 26  3Q'25  2Q'26  YTD 25
Revenues   386    1,325    3,741    19%   7%   15%
Profit (Loss) before Tax   14    49    124    -50%   -18%   -57%
(+) Net Finance Cost   33    112    359    56%   6%   80%
(+) Depreciation and Amortization   18    61    178    7%   5%   7%
(=) EBITDA   65    222    660    -2%   0%   1%
(+) Adjustments   2.7    9.2    15.3                
(a) Pre-operating expenses   0.1    0.3    0.7                
(b) Business development expenses   1.5    5.2    6.0                
(c) Stock-based consideration   1.1    3.7    8.5                
(d) Personnel non-recurring compensation   0.0    0.0    0.0                
(=) Adjusted EBITDA   67    231    676    0%   2%   -3%
Adjusted EBITDA Margin        17.5%   18.1%    -3.3 p.p.    -0.9 p.p.    -3.3 p.p. 

 

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

 

Segment Adjusted EBITDA Margin

 

For the three months ended September 30, 2026 

   Healthcare Services Mexico  Healthcare Services Peru  Oncosalud Peru  Healthcare Services Colombia  Holding and eliminations  Consolidated Reportable Segments
Revenues   316    307    323    494    (115)   1,325 
Profit (Loss) before Tax   11    21    53    15    (52)   49 
(+) Net Finance Cost   41    4    4    14    49    112 
(+) Depreciation and Amortization   24    11    10    14    3    61 
(=) Segment EBITDA   76    36    67    43    0    222 
(+) Adjustments   7.3    0.4    0.4    0.2    0.8    9.2 
Pre-operating expenses   0.1    0.0    0.0    0.0    0.3    0.3 
Business development expenses   5.2    0.0    0.0    0.0    0.0    5.2 
Stock-based consideration   2.1    0.4    0.4    0.2    0.6    3.7 
Personnel non-recurring compensation   0.0    0.0    0.0    0.0    0.0    0.0 
(=) Segment Adjusted EBITDA   83    37    68    43    1    231 
Adjusted EBITDA Margin   26.3%   11.9%   20.9%   8.8%        17.5%

 

16 

 

 For the three months ended September 30, 2025

   Healthcare Services Mexico  Healthcare Services Peru  Oncosalud Peru  Healthcare Services Colombia  Holding and eliminations  Consolidated Reportable Segments
Revenues   264    279    294    369    (88)   1,117 
Profit (Loss) before Tax   21    20    54    33    (31)   97 
(+) Net Finance Cost   33    9    3    6    21    72 
(+) Depreciation and Amortization   22    12    9    11    3    57 
(=) Segment EBITDA   76    42    65    49    (7)   226 
(+) Adjustments   0.9    1.8    1.8    1.8    0.3    6.6 
Pre-operating expenses   0.0    0.0    0.0    0.0    -0.3    -0.3 
Business development expenses   -1.0    1.6    1.6    1.7    0.0    3.8 
Stock-based consideration   1.9    0.2    0.2    0.1    0.6    3.0 
Personnel non-recurring compensation   0.0    0.0    0.0    0.0    0.0    0.0 
(=) Segment Adjusted EBITDA   77    44    67    51    (6)   232 
Adjusted EBITDA Margin   29.0%   15.7%   22.9%   13.9%        20.8%

 

Year to date September 30, 2026 

   Healthcare Services Mexico  Healthcare Services Peru  Oncosalud Peru  Healthcare Services Colombia  Holding and eliminations  Consolidated Reportable Segments
Revenues   895    885    954    1,321    (314)   3,741 
Profit (Loss) before Tax   22    54    154    80    (186)   124 
(+) Net Finance Cost   131    15    17    27    169    359 
(+) Depreciation and Amortization   70    32    31    36    8    178 
(=) Segment EBITDA   223    102    202    144    (10)   660 
(+) Adjustments   11.7    0.4    0.6    0.3    2.4    15.3 
Pre-operating expenses   0.1    0.0    0.0    0.0    0.6    0.7 
Business development expenses   6.0    0.0    0.0    0.0    0.0    6.0 
Stock-based consideration   5.5    0.4    0.6    0.3    1.7    8.5 
Personnel non-recurring compensation   0.0    0.0    0.0    0.0    0.0    0.0 
(=) Segment Adjusted EBITDA   234    102    202    145    -7    676 
Adjusted EBITDA Margin   26.2%   11.5%   21.2%   10.9%        18.1%

 

 Year to date September 30, 2025

   Healthcare Services Mexico  Healthcare Services Peru  Oncosalud Peru  Healthcare Services Colombia  Holding and eliminations  Consolidated Reportable Segments
Revenues   781    812    861    1,054    (253)   3,253 
Profit (Loss) before Tax   41    54    152    105    (62)   291 
(+) Net Finance Cost   106    27    13    13    39    199 
(+) Depreciation and Amortization   65    36    27    31    8    166 
(=) Segment EBITDA   212    117    192    148    (15)   655 
(+) Adjustments   32.5    2.1    2.1    1.9    2.2    40.9 
Pre-operating expenses   0.0    0.0    0.0    0.0    0.4    0.4 
Business development expenses   26.6    1.6    1.6    1.7    0.0    31.5 
Stock-based consideration   5.3    0.5    0.5    0.2    1.8    8.3 
Personnel non-recurring compensation   0.6    0.0    0.0    0.0    0.0    0.6 
(=) Segment Adjusted EBITDA   245    119    194    150    -13    696 
Adjusted EBITDA Margin   31.4%   14.7%   22.6%   14.3%        21.4%

 

Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.

 

Consolidated Peru Adjusted EBITDA Margin: is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment, net of inter-segment eliminations.

 

17 

 

Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below.

 

Adjusted Net Income

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   3Q'26 (USD)  3Q'26  3Q'25  YTD 26  YTD 25
Net Income (Loss)   7    24    53    67    175 
(a) Pre-operating expenses   0.1    0.3    (0.3)   0.7    0.4 
(b) Business development expenses   1.5    5.2    3.8    6.0    31.5 
(c) Stock-based consideration   1.1    3.7    3.0    8.5    8.3 
(d) Personnel non-recurring compensation   0.0    0.0    0.0    0.0    0.6 
(e) Non-cash and non-recurring financial costs   1.6    5.6    1.1    16.4    1.1 
(f) Allocated tax effects   (1.4)   (4.8)   (3.0)   (7.5)   (16.0)
(=) Adjusted Net Income   10    35    58    91    201 

 

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

(e) Non-cash and non-recurring financial costs include: 1) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT; and 2) withholding tax expenses associated with financing and refinancing activities.

(f) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.

 

Basic and Diluted Earnings per Share: Basic and Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

 

Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

 

18 

 

Adjusted Basic and Diluted Earnings per Share

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   3Q'26 (USD)  3Q'26  3Q'25  YTD 26  YTD 25
Net Income (Loss)   7    24    53    67    175 
Income (Loss) attributable to Owner of the company   6    20    48    56    166 
Weighted average number of basic and diluted shares at September 30        74.2    74.2    74.2    74.2 
Basic and diluted earnings per share   0.08    0.27    0.65    0.76    2.23 
Adjusted Net Income (Loss)   10    35    58    91    201 
Income (Loss) attributable to owners of Adjusted Net Income   9    30    53    81    191 
Weighted average number of basic and diluted shares at September 30        74.2    74.2    74.2    74.2 
Adjusted Basic and Diluted Earnings per Share   0.12    0.41    0.71    1.09    2.58 

 

Leverage Ratio: We calculate Leverage Ratio as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Adjusted Last Twelve Months EBITDA.

 

Leverage Ratio 

(Figures in millions of Soles, unless expressed otherwise)

 

   Sep-25  Dec-25  Sep-26
          
Current and non-current loans & borrowings   3,526    3,533    3,600 
Current and non-current lease liabilities   129    124    146 
Cash and cash equivalents   226    335    614 
Net Debt   3,429    3,321    3,133 
Adjusted LTM EBITDA   951    917    896 
Leverage Ratio   3.6x   3.6x   3.5x

 

Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents.

 

Net Debt 

(Figures in millions of Soles, unless expressed otherwise)

 

   Sep-25  Dec-25  Sep-26
          
(+) Loans and borrowings   3,526    3,533    3,600 
Short term debt   658    316    465 
Long term debt   2,868    3,216    3,136 
(+) Lease Liabilities   129    124    146 
Gross Debt   3,655    3,656    3,746 
(-) Cash and cash equivalents   226    335    614 
Net Debt   3,429    3,321    3,133 

 

19 

 

Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities.

 

Free Cash Flow Reconciliation 

(Figures in millions of Soles, unless expressed otherwise)

 

   Sep-25  Sep-26
       
       
Cash generated from operating activities   582    753 
(-) Income tax   155    54 
(+) Interest received   13    14 
Net cash from operating activities   440    713 
Net cash used in investing activities   (119)   (86)
Free Cash Flow   321    626 

  

FX Neutral: FX Neutral (“FXN”) measures are prepared and presented to eliminate the effect of foreign exchange, or “FX,” volatility between the comparison periods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, which may not be indicative of core operating results and business outlook.

 

FX Neutral measures are presented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analysts and the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or any other generally accepted accounting principles and should not be considered as a measure of performance in isolation.

 

The FX Neutral measures were calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these preceding periods until the date of the Company’s most recent financial information.

 

The FX Neutral measures for the three months ended September 30, 2025 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the key business metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (MXN 5.2713 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (COP 1,131.3043 to PEN 1.00); then using such results to re-translate the corresponding amounts back to Peruvian soles by dividing them by the average Mexican pesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2026 (MXN 5.1038 to PEN 1.00 / COP 943.2503 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics would have been had exchange rates remained stable from this past period until the three months ended September 30, 2026.

 

20 

 

Safe Harbor Statement

 

This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “project,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the execution of our strategic plan, including the recovery of our growth levels, our planned investments, our revenue, Adjusted EBITDA and capital expenditure guidance, our expectation for revenue and Adjusted EBITDA growth, the timeline for the construction and commencement of operations at the Centro Ambulatorio Trecca in Lima and our ability to recover any loss under the oncology risk-sharing contract in Colombia. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.

 

The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the “SEC”).

 

Financial Guidance Disclaimer

 

Auna′s guidance is based on management’s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.

 

Auna’s  financial guidance reflects management’s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company’s Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the Leverage Ratio target and Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the “Safe Harbor Statement” section in this release.

 

21 

 

IR Contact

 

Email: contact@aunainvestors.com

 

- Financial Tables Follow –

 

22 

 

Balance Sheet (1/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

  

Sep-26

(USD)

  Sep-26  Dec-25 

Δ Sep-26

vs Dec-25

Assets                    
Current assets                    
Cash and cash equivalents   179    614    335    278 
Trade accounts receivable   345    1,185    1,043    143 
Other assets   61    211    259    (48)
Inventories   46    158    165    (7)
Insurance contract assets   —      —      13    (13)
Other investments   1    3    30    (27)
Total current assets   632    2,171    1,845    326 
Non-current assets                    
Trade accounts receivable   0    0    0    (0)
Other assets   9    30    27    3 
Investments in associates and joint venture   10    35    30    5 
Property furniture and equipment   701    2,405    2,287    118 
Intangible assets   824    2,829    2,704    125 
Right-of-use assets   38    131    113    18 
Investment properties   2    7    6    0 
Derivative financial instruments   16    56    54    2 
Deferred tax assets   82    282    231    52 
Other investments   0    1    1    (0)
Total non-current assets   1,683    5,776    5,454    323 
Total assets   2,315    7,947    7,298    649 

 

23 

 

Balance Sheet (2/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

  

Sep-26

(USD)

  Sep-26  Dec-25 

Δ Sep-26

vs Dec-25

Liabilities            
Current liabilities                    
Loans and borrowings   135    465    316    148 
Lease liabilities   10    34    29    5 
Trade accounts payable   348    1,196    1,053    143 
Other accounts payable   85    291    225    65 
Provisions   4    13    10    3 
Derivative financial instruments   8    28    23    5 
Insurance contract liabilities   5    18    9    9 
Deferred income   0    1    0    0 
Total current liabilities   596    2,046    1,667    379 
Non-current liabilities                    
Loans and borrowings   913    3,136    3,216    (80)
Lease liabilities   33    112    94    18 
Trade accounts payable   0    0    1    (1)
Other accounts payable   69    236    222    14 
Derivative financial instruments   6    21    40    (18)
Deferred tax liabilities   80    276    291    (15)
Deferred income   0    1    0    1 
Total non-current liabilities   1,102    3,783    3,865    (82)
Total liabilities   1,698    5,828    5,532    297 

 

Total equity   617    2,119    1,766    352 
Total liabilities and equity   2,315    7,947    7,298    649 

 

24 

 

Income Statement

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

    

3Q'26

(USD)

    3Q'26    YTD 26    

Δ 3Q'26

vs 3Q'25

    

Δ YTD 26

vs YTD 25

 
Revenue                         
Healthcare Services Mexico   92    316    895    20%   15%
Healthcare Services Colombia   144    493    1,318    35%   26%
- Healthcare Services Colombia   144    494    1,321    34%   25%
- Holding and eliminations   (0)   (1)   (4)   -74%   -4%
Healthcare Services Peru & Oncosalud Peru   150    516    1,528    6%   7%
- Healthcare Services Peru   89    307    885    10%   9%
- Oncosalud Peru   94    323    954    10%   11%
- Holding and eliminations   (33)   (114)   (310)   35%   24%
Total Revenue   386    1,325    3,741    19%   15%
Cost of sales and services   (256)   (879)   (2,421)   26%   20%
Gross profit   130    446    1,319    6%   7%
Gross margin        33.7%   35.3%   -3.9 p.p.    -2.7 p.p. 
Selling expenses   (18)   (62)   (186)   5%   12%
Administrative expenses   (68)   (232)   (678)   16%   15%
(Loss) reversal for impairment of trade receivables   (1)   (3)   (11)   -48%   -62%
Other income and expenses, net   3    10    31    -13%   -4%
Operating profit   46    158    475    -4%   -1%
Finance income   2    7    15    63%   -1%
Finance income from exchange difference   0    0    0    -100%   -100%
Finance costs   (35)   (119)   (355)   3%   -1%
Finance costs from exchange difference   —      —      (19)   —      —   
Net finance cost   (33)   (112)   (359)   56%   80%
Share of profit of equity accounted investees   1    3    8    -8%   -5%
Profit (loss) before tax   14    49    124    -50%   -57%
Income tax expense (benefit)   (7)   (24)   (58)   -45%   -50%
Net Income (Loss)   7    24    67    -54%   -62%
EBITDA                         
Healthcare Services Mexico   22    76    223    0%   5%
Healthcare Services Colombia   13    43    144    -13%   -3%
Healthcare Services Peru & Oncosalud Peru   30    103    303    -4%   -2%
- Healthcare Services Peru   11    36    102    -14%   -13%
- Oncosalud Peru   20    67    202    2%   5%
Holding and eliminations   0    0    (10)          
Total EBITDA   65    222    660    -2%   1%
Adjusted EBITDA                         
Healthcare Services Mexico   24    83    234    8%   -4%
Healthcare Services Colombia   13    43    145    -16%   -4%
Healthcare Services Peru & Oncosalud Peru   30    104    304    -6%   -3%
- Healthcare Services Peru   11    37    102    -16%   -15%
- Oncosalud Peru   20    68    202    0%   4%
Holding and eliminations   0    1    (7)          
Total Adjusted EBITDA   67    231    676    0%   -3%
Adjusted EBITDA Margin                         
Healthcare Services Mexico        26.3%   26.2%   -2.7 p.p.    -5.2 p.p. 
Healthcare Services Colombia        8.8%   10.9%   -5.1 p.p.    -3.3 p.p. 
Healthcare Services Peru & Oncosalud Peru        20.2%   19.9%   -2.6 p.p.    -2.1 p.p. 
- Healthcare Services Peru        11.9%   11.5%   -3.8 p.p.    -3.2 p.p. 
- Oncosalud Peru        20.9%   21.2%   -2.0 p.p.    -1.4 p.p. 
Adjusted EBITDA Margin        17.5%   18.1%   -3.3 p.p.    -3.3 p.p. 

 

25 

 

Statement of Cash Flows (1/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   YTD 26 (USD)  YTD 26  YTD 25 

Δ YTD 26

vs YTD 25

Cash flows from operating activities                    
(Loss) profit for the period   19    67    175    (108)
Adjustments for:                    
Depreciation   27    91    86    5 
Depreciation of right-of-use assets   6    22    21    1 
Amortization   19    64    59    5 
(Reversal) Impairment of inventories   0    1    0    0 
Equity-settled share-based payment transactions   2    9    8    0 
Gain (loss) on disposal of property furniture and equipment   0    0    (1)   2 
Loss on disposal of right-of-use assets net of leases   —      —      (0)   0 
(Reversal) loss for impairment of trade receivables   3    11    29    (18)
Share of profit of equity-accounted investees   (2)   (8)   (8)   0 
Technical provisions and other provisions   1    5    1    4 
Finance income   (4)   (15)   (161)   145 
Finance costs   109    374    359    15 
Tax expense   17    58    116    (58)
Net changes in assets and liabilities                    
Trade accounts receivable and other assets   (21)   (72)   (132)   60 
Inventories   5    19    (1)   20 
Trade accounts payable and other accounts payable   32    109    35    73 
Provisions and employee benefits   (1)   (2)   (4)   1 
Insurance contract liabilities   6    22    (1)   23 
Cash generated from operating activities   219    753    582    171 
Income tax paid   (16)   (54)   (155)   101 
Interest received   4    14    13    0 
Net cash from operating activities   208    713    440    273 

  

26 

 

Statement of Cash Flows (2/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   YTD 26 (USD)  YTD 26  YTD 25 

Δ YTD 26

vs YTD 25

Cash flows from investing activities            
Payment for accounts payables to former shareholder   (2)   (6)   (21)   14 
Purchase of properties furniture and equipment   (21)   (71)   (66)   (4)
Purchase of intangibles   (12)   (41)   (47)   6 
Dividends from equity-accounted investees   1    2    3    (1)
Purchase of other investments, net of sales   8    29    5    24 
Proceeds from sale of property furniture and equipment   0    0    6    (6)
Net cash used in investing activities   (25)   (86)   (119)   33 
Cash flows from financing activities                    
Proceeds from settlement of derivatives - interest rate swaps   (6)   (19)   (9)   (10)
Proceeds from loans and borrowings   82    282    1,079    (797)
Payment for loans and borrowings   (102)   (349)   (1,084)   735 
Payment for lease liabilities   (10)   (34)   (34)   (0)
Penalty paid for debt prepayment   (0)   (0)   (0)   (0)
Payment for derivatives premiums   (4)   (15)   (17)   2 
Interest paid   (66)   (228)   (271)   43 
Net cash used in financing activities   (106)   (363)   (336)   (27)
Net (decrease) increase in cash and cash equivalents   77    263    (15)   279 
Cash and cash equivalents at January 1   98    335    236    100 
 Effect of movements in exchange rates on cash held   4    15    5    10 
 Cash and cash equivalents at the end of the period   179    614    226    388 

 

27 

 

Historical Financial Metrics

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

 

   3Q'24  4Q'24  1Q'25  2Q'25  3Q'25  4Q'25  1Q'26  2Q'26  3Q'26
Revenue                                             
Oncosalud Peru   273    276    281    286    294    304    314    317    323 
Healthcare Services Peru   255    245    263    269    279    273    281    296    307 
Healthcare Services Colombia   363    353    339    346    369    387    400    427    494 
Healthcare Services Mexico   316    268    243    274    264    258    279    300    316 
Holding and eliminations   (80)   (79)   (84)   (81)   (88)   (89)   (96)   (103)   (115)
Total revenue from contracts with customers   1,127    1,063    1,042    1,094    1,117    1,133    1,178    1,238    1,325 
Cost of sales and services   (677)   (629)   (660)   (660)   (698)   (704)   (747)   (796)   (879)
Gross profit   449    434    382    434    419    429    431    442    446 
Selling expenses   (55)   (42)   (54)   (54)   (59)   (54)   (62)   (62)   (62)
Administrative expenses   (195)   (201)   (182)   (208)   (200)   (222)   (214)   (232)   (232)
Impairment losses on trade receivables   (25)   (13)   (16)   (8)   (5)   (19)   (9)   0    (3)
Other expenses   0    (2)   0    0    0    0    0    0    0 
Other income   54    14    9    12    11    11    9    13    10 
Operating profit   229    190    139    176    166    144    155    162    158 
Finance income   6    7    6    5    4    6    4    5    7 
Finance income from exchange difference   28    (31)   37    68    40    48    0    0    0 
Finance costs   (138)   (138)   (123)   (120)   (116)   (292)   (118)   (118)   (119)
Finance costs from exchange difference   0    8    0    0    0    0    (26)   8    0 
Net finance cost   (103)   (155)   (80)   (46)   (72)   (238)   (141)   (105)   (112)
Share of profit of equity-accounted investees   2    2    3    2    3    2    3    2    3 
Profit (loss) before tax   127    37    62    132    97    (91)   16    59    49 
Income tax (expense) benefit   (27)   (13)   (24)   (48)   (44)   27    (7)   (26)   (24)
Net Income   101    24    38    84    53    (64)   9    33    24 
EBITDA   286    244    195    234    226    203    215    223    222 
EBITDA Adjustments                                             
Net Income   101    24    38    84    53    (64)   9    33    24 
Income tax expense   27    13    24    48    44    (27)   7    26    24 
Net finance cost   103    155    80    46    72    238    141    105    112 
Depreciation and amortization   55    52    53    55    57    56    57    59    61 
(a) Pre-operating expenses   0    0    0    0    (0)   0    0    0    0 
(b) Business development expenses   (44)   3    24    4    4    10    0    1    5 
(c) Change in fair value of earn-out liabilities   0    0    0    0    0    0    0    0    0 
(d) Stock-based consideration   6    3    3    3    3    3    2    3    4 
(e) Personnel non-recurring compensation   2    5    0    0    0    5    0    0    0 
(f) Change in fair value of investment properties   0    0    0    0    0    0    0    0    0 
Adjusted EBITDA   250    254    222    241    232    220    217    227    231 

 

28 

 

Key Operating Metrics

 

   3Q'26  YTD 26 

Δ 3Q'26

vs 3Q'25

 

Δ YTD 26

vs YTD 25

Oncosalud Peru            
Plan memberships (1) (2)   1,441,794    1,441,794    3%   3%
Average monthly revenue per plan member (3)  S/       65.15   S/        64.02    5%   5%
Preventive check-ups (4)   25,084    81,883    -14%   -13%
Patients treated (5)   56,127    153,625    34%   28%
Medical loss ratio (6)        58.7%        4.2 p.p 
                     
Healthcare Services                    
Total bed capacity (1)(7)   2,252    2,252    1%   1%
Protected Lives (8)   3,208,686    3,208,686    6%   6%
Surgeries (9)   23,932    67,454    12%   7%
Emergency treatments (10)   101,257    290,540    8%   9%
Chemotherapies & Radiotherapies (11)   55,439    162,888    7%   6%
Total number of days hospitalized (12)   144,041    418,206    6%   5%
Operating capacity utilization (13)   78.4%   76.7%   3.2 p.p    2.3 p.p 
Total capacity utilization (14)   69.5%   68.0%   3.1 p.p    2.3 p.p 

 

1)As of period end.

2)As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of September 30, 2026, we had 1,341,825 active members and 99,969 inactive members.

3)Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period.

4)Preventive check-ups consider Oncosalud and Healthcare plan check-ups, including for Auna Corporate plans, receiving check-ups at the Centro de Bienestar Ambulatorio – CBA (Wellness Center) in Lima and at other facilities in Peru.

5)Number of individual plan members in Oncosalud and Healthcare plans, including Auna Corporate plans, receiving treatment during the period in Peru. Each plan member is counted once for a trimester, however, might have received multiple instances of treatment throughout the year.

6)MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans.

7)Includes all beds within the Healthcare Network and excludes 109 Oncology beds.

8)Insured population assigned to Auna under risk-sharing agreements in Colombia.

9)Number of surgeries includes surgeries, outpatient surgeries and cesarean sections.

10)Emergency care includes the number of visits in the emergency room and may include several visits per patient.

 

29 

 

11)Intravenous chemotherapy and radiotherapy infusions in both inpatient and outpatient care; excludes oral treatments. In Peru, includes sessions across the Healthcare Services Network and Oncosalud Segments.

12)Total number of days during which any of Auna’s beds were occupied by a hospitalized patient during the period, including ICU.

13)Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period.

14)Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.

 

30 

 

Exhibit 99.2

 

 

 

 

 

 

 

 

 

 

 

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Financial Statements

 

September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Auna S.A. and Subsidiaries

 

Condensed Consolidated Interim Financial Statements

 

 

September 30, 2026

 

 

 

 

Contents Page
Condensed Consolidated Interim Statement of Financial Position 1
Condensed Consolidated Interim Statement of Profit or Loss and Other  
Comprehensive Income 2
Condensed Consolidated Interim Statement of Changes in Equity 3
Condensed Consolidated Interim Statement of Cash Flows 4
Operating Segments 5 - 10

 

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Financial Position
As of September 30, 2026 and December 31, 2025

 

In thousands of soles September 30,
2026
  December 31, 2025  In thousands of soles

September 30,

2026

  December 31, 2025
Assets           Liabilities         
Current assets           Current liabilities         
Cash and cash equivalents  613,627    335,441   Loans and borrowings  464,590    316,339 
Trade accounts receivable  1,185,407    1042,792   Lease liabilities  34,339    29,282 
Other assets  210,509    258,511   Trade accounts payable  1,196,003    1,053,395 
Inventories  158,201    164,798   Other accounts payable  290,817    225,465 
Other investments  3,011    30,237   Provisions  13,407    10,161 
Insurance contract assets  —      12,778   Derivative financial instruments  27,595    22,903 
Total current assets  2,170,755    1,844,557   Insurance contract liabilities  18,307    9,447 
            Deferred income  560    98 
Non-current assets           Total current liabilities  2,045,618    1,667,090 
Trade accounts receivable  423    486             
Other assets  29,764    26,910   Non-current liabilities         
Investments in associates and joint venture  34,640    29,848   Loans and borrowings  3,135,770    3,216,171 
Property, furniture, and equipment  2,405,495    2,287,002   Lease liabilities  111,788    94,237 
Intangible assets  2,828,954    2,704,351   Trade accounts payable  431    1,450 
Right-of-use assets  130,967    113,116   Other accounts payable  235,836    221,940 
Investment properties  6,726    6,340   Derivative financial instruments  21,313    39,647 
Derivative financial instruments  56,380    54,036   Deferred tax liabilities  276,306    291,086 
Deferred tax assets  282,325    230,716   Deferred income  1,255    87 
Other investments  501    702   Total non-current liabilities  3,782,699    3,864,618 
Total non-current assets  5,776,175    5,453,507   Total liabilities  5,828,317    5,531,708 
                      
            Equity         
            Share capital  17,390    17,389 
            Share premium  1,210,778    1,209,715 
            Reserves  809,118    566,271 
            Retained losses  (122,739)   (192,615)
            Equity attributable to the owner of the Company  1,914,547    1,600,760 
            Non-controlling interest  204,066    165,596 
            Total equity  2,118,613    1,766,356 
Total assets  7,946,930    7,298,064   Total liabilities and equity  7,946,930    7,298,064 

 

1 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income
For the three and nine months ended September 30, 2026 and 2025

 

  

Three-month period

ended September 30

 

Nine-month period

ended September 30

In thousands of soles  2026  2025  2026  2025
Revenue                    
Insurance revenue   309,587    285,596    911,726    837,798 
Healthcare services revenue   929,145    744,365    2,574,350    2,163,424 
Sale of medicines   86,267    87,011    254,673    251,557 
Total revenue from contracts with customers   1,324,999    1,116,972    3,740,749    3,252,779 
Cost of sales and services   (878,922)   (697,849)   (2,421,347)   (2,017,637)
Gross profit   446,077    419,123    1,319,402    1,235,142 
Selling expenses   (62,345)   (59,114)   (186,315)   (166,941)
Administrative expenses   (232,178)   (199,831)   (677,892)   (590,463)
Loss for impairment of trade receivables   (2,845)   (5,481)   (10,893)   (28,825)
Other income   9,506    10,918    30,827    32,236 
Operating profit   158,215    165,615    475,129    481,149 
Finance income   6,940    4,269    15,200    15,356 
Finance income from exchange difference   86    39,686    86    145,202 
Finance costs   (119,180)   (115,730)   (355,289)   (359,232)
Finance costs from exchange difference   —      —      (18,514)   —   
Net finance cost   (112,154)   (71,775)   (358,517)   (198,674)
Share of profit of equity-accounted investees   2,680    2,899    7,693    8,073 
Profit before tax   48,741    96,739    124,305    290,548 
Income tax expense   (24,278)   (43,798)   (57,662)   (115,622)
Profit for the period   24,463    52,941    66,643    174,926 
Other comprehensive income                    
Items that are or may be reclassified subsequently to profit or loss                    
Cash flow hedges   11,370    (4,847)   14,593    (36,341)
Foreign operations – foreign currency translation differences   30,612    34,507    267,114    101,750 
Other investments at FVOCI – net change in fair value   12    410    (173)   1,036 
Income tax   (3,547)   1,405    (4,479)   10,667 
Other comprehensive income for the period, net of tax   38,447    31,475    277,055    77,112 
Total comprehensive income for the period   62,910    84,416    343,698    252,038 
Profit attributable to:                    
Owner of the Company   20,373    48,094    56,355    165,501 
Non-controlling interest   4,090    4,847    10,288    9,425 
    24,463    52,941    66,643    174,926 
Total comprehensive income attributable to:                    
Owner of the Company   51,464    79,791    305,228    240,315 
Non-controlling interest   11,446    4,625    38,470    11,723 
    62,910    84,416    343,698    252,038 
Earnings per share                    
Basic earnings per share   0.28    0.65    0.76    2.24 
Diluted earnings per share   0.27    0.65    0.76    2.23 

 

2 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Changes in Equity
For the nine months ended September 30, 2026 and 2025

 

      Equity attributable to the owner of the Company         
In thousands of soles 

Share

capital

 

Share

premium

  Other
capital
reserve
  Translation reserve 

Cost of
hedging

reserve

 

Hedging

reserve

 

Merger

and other reserves

  Share-
based
payment reserve
  Retained earnings (losses)  Total  Non-
controlling
interest
 

Total

equity

Balances as of December 31, 2024   17,387    1,208,586    93,012    (232,770)   15,392    (36,494)   676,491    9,145    (273,533)   1,477,216    145,724    1,622,940 
Balances as of January 1, 2025   17,387    1,208,586    93,012    (232,770)   15,392    (36,494)   676,491    9,145    (273,533)   1,477,216    145,724    1,622,940 
Profit for the period   —      —      —      —      —      —      —      —      165,501    165,501    9,425    174,926 
Other comprehensive income for the period   —      —      —      99,452    (38,709)   13,035    1,036    —      —      74,814    2,298    77,112 
Total comprehensive income for the period   —      —      —      99,452    (38,709)   13,035    1,036    —      165,501    240,315    11,723    252,038 
Issuance of shares   2    1,129    —      —      —      —      —      (1,131)   —      —      —      —   
Equity transaction for mandatory purchase of NCI   —      —      —      —      —      —      (68,111)   —      —      (68,111)   —      (68,111)
Equity-settled share-based payment   —      —      —      —      —      —      —      8,330    —      8,330    —      8,330 
Total transactions with the owner of the Company   2    1,129    —      —      —      —      (68,111)   7,199    —      (59,781)   —      (59,781)
Balances as of September 30, 2025   17,389    1,209,715    93,012    (133,318)   (23,317)   (23,459)   609,416    16,344    (108,032)   1,657,750    157,447    1,815,197 
Balances as of December 31, 2025   17,389    1,209,715    109,708    (148,652)   (21,146)   —      607,155    19,206    (192,615)   1,600,760    165,596    1,766,356 
Profit for the period   —      —      —      —      —      —      —      —      56,355    56,355    10,288    66,643 
Other comprehensive income for the period   —      —      —      238,932    21,062    (10,948)   (173)   —      —      248,873    28,182    277,055 
Total comprehensive income for the period   —      —      —      238,932    21,062    (10,948)   (173)   —      56,355    305,228    38,470    343,698 
Issuance of shares   1    1,063    —      —      —      —      —      (1,064)   —      —      —      —   
Equity-settled share-based payment   —      —      —      —      —      —      —      8,559    —      8,559    —      8,559 
Transfer from legal reserve   —      —      (13,521)   —      —      —      —      —      13,521    —      —      —   
Total transactions with the owner of the Company   1    1,063    (13,521)   —      —      —      —      7,495    13,521    8,559    —      8,559 
Balances as of September 30, 2026   17,390    1,210,778    96,187    90,280    (84)   (10,948)   606,982    26,701    (122,739)   1,914,547    204,066    2,118,613 

 

3 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Cash Flows
For the nine months ended September 30, 2026 and 2025

 

   Nine-month period ended September 30
In thousands of soles  2026  2025
Cash flows from operating activities          
Profit for the period   66,643    174,926 
Adjustments for:          
Depreciation   91,467    86,118 
Depreciation of right-of-use assets   22,178    21,321 
Amortization   63,946    58,559 
Impairment of inventories   609    120 
Equity-settled share-based payment transactions   8,559    8,330 
Loss (gain) on disposal of property, furniture, and equipment   346    (1,275)
Gain on disposal of right-of-use assets net of leases liabilities   —      (9)
Impairment of trade receivables   10,893    28,825 
Share of profit of equity-accounted investees   (7,693)   (8,073)
Provisions   4,686    1,108 
Finance income   (15,286)   (160,558)
Finance costs   373,803    359,232 
Tax expense   57,662    115,622 
Net changes in assets and liabilities:          
Trade accounts receivable and other assets   (72,121)   (132,035)
Inventories   18,704    (1,443)
Trade accounts payable and other accounts payable   108,724    35,230 
Provisions and other reserves   (2,019)   (3,514)
Insurance contract liabilities, net   21,828    (753)
Cash generated from operating activities   752,929    581,731 
Income tax paid   (54,131)   (155,234)
Interest received   13,755    13,281 
Net cash from operating activities   712,553    439,778 
Cash flows from investing activities          
Payment for accounts payable to former shareholder   (6,463)   (20,855)
Purchase of properties, furniture, and equipment   (70,564)   (66,405)
Proceeds from sale of property, furniture, and equipment   20    6,493 
Purchase of intangibles   (40,563)   (46,556)
Dividends from equity-accounted investees   2,196    3,169 
Proceeds from sales of other investments, net of purchase   29,077    5,249 
Net cash used in investing activities   (86,297)   (118,905)
Cash flows from financing activities          
Proceeds from loans and borrowings   282,176    1,078,860 
Payment for loans and borrowings   (349,190)   (1,084,162)
Payment for lease liabilities   (33,521)   (33,516)
Penalty paid for debt prepayment   (163)   (81)
Payment for derivatives premiums   (14,911)   (16,863)
Interest paid   (228,064)   (271,105)
Proceeds from settlement of derivatives - interest rate swaps   (19,273)   (9,336)
Net cash used in financing activities   (362,946)   (336,203)
Net increase (decrease) in cash and cash equivalents   263,310    (15,330)
Cash and cash equivalents at January 1   335,441    235,745 
Effect of movements in exchange rates on cash held   14,876    5,295 
Cash and cash equivalents at September 30   613,627    225,710 
Transactions not representing cash flows          
Assets acquired through finance lease and other financing   40,062    10,493 
Assets acquired from suppliers in installments   1,230    22,163 

 

4 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

Operating Segments

 

A.Basis for segmentation

The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.

 

The following summary describes the operations of each reportable segment.

 

Reportable segments Operations
Oncosalud Peru Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer.
Healthcare services in Peru Corresponds to medical services within the network of clinics and health centers in Peru.
Healthcare services in Colombia Corresponds to medical services within the network of clinics and health centers in Colombia.
Healthcare services in Mexico Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico.

 

B.Information about reportable segments

Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.

 

5 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

For the three months period ended September 30, 2026:

 

   Reportable segments      
In thousands of soles  

Oncosalud

Peru 

  Healthcare services in Peru

  Healthcare services in Colombia  Healthcare services in Mexico  Total reportable segments  Holding and eliminations  Total
2026                                   
External revenues   308,427    207,463    493,179    315,930    1,324,999    —      1,324,999 
Inter-segment revenue (i)   14,256    99,764    1,028    —      115,048    (115,048)   —   
Segment revenue   322,683    307,227    494,207    315,930    1,440,047    (115,048)   1,324,999 
External cost of service   (80,587)   (212,520)   (390,991)   (194,824)   (878,922)   —      (878,922)
Inter-segment cost of service (i)   (103,877)   (14,188)   —      —      (118,065)   118,065    —   
Segment cost of service   (184,464)   (226,708)   (390,991)   (194,824)   (996,987)   118,065    (878,922)
Gross profit   138,219    80,519    103,216    121,106    443,060    3,017    446,077 
External selling expenses   (47,359)   (7,757)   (1,567)   (3,098)   (59,781)   (2,564)   (62,345)
Segment selling expenses   (47,359)   (7,757)   (1,567)   (3,098)   (59,781)   (2,564)   (62,345)
External administrative expenses   (20,968)   (32,326)   (68,661)   (70,022)   (191,977)   —      (191,977)
Inter-segment administrative expenses   (1,123)   (3,183)   —      —      (4,306)   4,306    —   
Corporate expenses   (17,340)   (14,750)   (3,297)   (3,208)   (38,595)   (1,606)   (40,201)
Segment administrative expenses   (39,431)   (50,259)   (71,958)   (73,230)   (234,878)   2,700    (232,178)
Impairment losses on trade receivables   (374)   680    (3,408)   257    (2,845)   —      (2,845)
Other income   474    1,822    1,075    1,758    5,129    4,377    9,506 
Inter-segment other income   4,221    199    —      5,377    9,797    (9,797)   —   
Other income   4,695    2,021    1,075    7,135    14,926    (5,420)   9,506 
Segment operating profit (loss)   55,750    25,204    27,358    52,170    160,482    (2,267)   158,215 
Share of profit of equity accounted investees, net of taxes   889    —      1,790    —      2,679    1    2,680 
Exchange difference, net   572    (270)   12,830    1,079    14,211    (14,125)   86 
Interest expense, net   (4,403)   (4,039)   (26,653)   (41,999)   (77,094)   (35,146)   (112,240)
Segment profit (loss) before tax   52,808    20,895    15,325    11,250    100,278    (51,537)   48,741 
Other disclosures                                   
Depreciation and amortization   (10,452)   (10,999)   (13,906)   (23,508)   (58,865)   (2,525)   (61,390)
Capital expenditure   (19,789)   (16,663)   (18,424)   (15,365)   (70,241)   (7,649)   (77,890)
Segment assets   49,025    (29,024)   140,751    (68,768)   91,984    59,254    151,238 
Segment liabilities   16,369    (42,499)   84,874    (54,868)   3,876    80,787    84,663 

 

6 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

For the three months period ended September 30, 2025:

 

   Reportable segments      
In thousands of soles  

Oncosalud

Peru 

  Healthcare services in Peru

  Healthcare services in Colombia  Healthcare services in Mexico  Total reportable segments  Holding and eliminations  Total
2025                     
External revenues   286,410    201,887    364,566    264,109    1,116,972    —      1,116,972 
Inter-segment revenue (i)   7,287    77,203    3,957    —      88,447    (88,447)   —   
Segment revenue   293,697    279,090    368,523    264,109    1,205,419    (88,447)   1,116,972 
External cost of service   (83,944)   (185,953)   (275,633)   (152,319)   (697,849)   —      (697,849)
Inter-segment cost of service (i)   (73,209)   (9,290)   —      —      (82,499)   82,499    —   
Segment cost of service   (157,153)   (195,243)   (275,633)   (152,319)   (780,348)   82,499    (697,849)
Gross profit   136,544    83,847    92,890    111,790    425,071    (5,948)   419,123 
External selling expenses   (47,813)   (6,140)   (1,245)   (3,892)   (59,090)   (24)   (59,114)
Segment selling expenses   (47,813)   (6,140)   (1,245)   (3,892)   (59,090)   (24)   (59,114)
External administrative expenses   (18,545)   (29,996)   (51,212)   (58,424)   (158,177)   —      (158,177)
Inter-segment administrative expenses   (757)   (2,037)   —      —      (2,794)   2,794    —   
Corporate expenses   (17,266)   (17,096)   (2,462)   (1,735)   (38,559)   (3,095)   (41,654)
Segment administrative expenses   (36,568)   (49,129)   (53,674)   (60,159)   (199,530)   (301)   (199,831)
Impairment losses on trade receivables   (573)   (1,138)   (2,405)   (1,379)   (5,495)   14    (5,481)
Other income   960    1,889    1,029    7,146    11,024    (106)   10,918 
Inter-segment other income   3,002    238    —      —      3,240    (3,240)   —   
Other income   3,962    2,127    1,029    7,146    14,264    (3,346)   10,918 
Segment operating profit (loss)   55,552    29,567    36,595    53,506    175,220    (9,605)   165,615 
Share of profit of equity accounted investees, net of taxes   782    —      2,117    —      2,899    —      2,899 
Exchange difference, net   756    483    17,255    8,471    26,965    12,721    39,686 
Interest expense, net   (3,397)   (9,838)   (23,032)   (41,453)   (77,720)   (33,741)   (111,461)
Segment profit (loss) before tax   53,693    20,212    32,935    20,524    127,364    (30,625)   96,739 
Other disclosures                                   
Depreciation and amortization   (9,164)   (12,397)   (10,749)   (22,205)   (54,515)   (2,796)   (57,311)
Capital expenditure   (7,351)   (4,297)   (5,104)   (9,583)   (26,335)   (3,118)   (29,453)
Segment assets   95,919    41,289    80,639    46,250    264,097    (149,202)   114,895 
Segment liabilities   64,688    30,808    103,753    34,908    234,157    (138,445)   95,712 

 

7 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

For the nine months period ended September 30, 2026:

 

   Reportable segments      
In thousands of soles  

Oncosalud

Peru 

  Healthcare services in Peru

  Healthcare services in Colombia  Healthcare services in Mexico  Total reportable segments  Holding and eliminations  Total
2026                     
External revenues   912,226    616,001    1,317,500    895,022    3,740,749    —      3,740,749 
Inter-segment revenue (i)   41,479    268,732    3,816    —      314,027    (314,027)   —   
Segment revenue   953,705    884,733    1,321,316    895,022    4,054,776    (314,027)   3,740,749 
External cost of service   (260,115)   (607,753)   (1,019,087)   (534,392)   (2,421,347)   —      (2,421,347)
Inter-segment cost of service (i)   (269,509)   (39,419)   —      —      (308,928)   308,928    —   
Segment cost of service   (529,624)   (647,172)   (1,019,087)   (534,392)   (2,730,275)   308,928    (2,421,347)
Gross profit   424,081    237,561    302,229    360,630    1,324,501    (5,099)   1,319,402 
External selling expenses   (151,083)   (20,379)   (4,100)   (9,087)   (184,649)   (1,666)   (186,315)
Segment selling expenses   (151,083)   (20,379)   (4,100)   (9,087)   (184,649)   (1,666)   (186,315)
External administrative expenses   (59,578)   (98,462)   (186,536)   (210,034)   (554,610)   —      (554,610)
Inter-segment administrative expenses   (3,105)   (5,973)   —      —      (9,078)   9,078    —   
Corporate expenses   (53,950)   (45,813)   (11,353)   (9,563)   (120,679)   (2,603)   (123,282)
Segment administrative expenses   (116,633)   (150,248)   (197,889)   (219,597)   (684,367)   6,475    (677,892)
Impairment losses on trade receivables   (1,046)   (3,619)   (4,576)   (1,652)   (10,893)   —      (10,893)
Other income   1,564    5,145    6,989    17,257    30,955    (128)   30,827 
Inter-segment other income   10,975    663    —      5,377    17,015    (17,015)   —   
Other income   12,539    5,808    6,989    22,634    47,970    (17,143)   30,827 
Segment operating profit (loss)   167,858    69,123    102,653    152,928    492,562    (17,433)   475,129 
Share of profit of equity accounted investees, net of taxes   2,485    —      5,207    —      7,692    1    7,693 
Exchange difference, net   (3,044)   (978)   51,115    (31)   47,062    (65,490)   (18,428)
Interest expense, net   (13,470)   (14,235)   (78,527)   (130,510)   (236,742)   (103,347)   (340,089)
Segment profit (loss) before tax   153,829    53,910    80,448    22,387    310,574    (186,269)   124,305 
Other disclosures                                   
Depreciation and amortization   (31,463)   (32,430)   (36,460)   (69,645)   (169,998)   (7,593)   (177,591)
Capital expenditure   (33,268)   (32,452)   (30,290)   (40,172)   (136,182)   (16,237)   (152,419)
Segment assets   2,498,708    1,008,909    2,951,326    3,216,161    9,675,104    (1,728,174)   7,946,930 
Segment liabilities   1,102,755    563,229    1,613,557    1,979,037    5,258,578    569,739    5,828,317 

 

8 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

For the nine months period ended September 30, 2025:

 

   Reportable segments      
In thousands of soles  

Oncosalud

Peru 

  Healthcare services in Peru

  Healthcare services in Colombia  Healthcare services in Mexico  Total reportable segments  Holding and eliminations  Total
2025                     
External revenues   833,399    589,160    1,049,582    780,638    3,252,779    —      3,252,779 
Inter-segment revenue (i)   27,124    222,345    3,957    —      253,426    (253,426)   —   
Segment revenue   860,523    811,505    1,053,539    780,638    3,506,205    (253,426)   3,252,779 
External cost of service   (236,766)   (541,383)   (774,499)   (464,989)   (2,017,637)   —      (2,017,637)
Inter-segment cost of service (i)   (220,437)   (24,475)   —      —      (244,912)   244,912    —   
Segment cost of service   (457,203)   (565,858)   (774,499)   (464,989)   (2,262,549)   244,912    (2,017,637)
Gross profit   403,320    245,647    279,040    315,649    1,243,656    (8,514)   1,235,142 
External selling expenses   (139,235)   (16,127)   (3,912)   (8,625)   (167,899)   958    (166,941)
Segment selling expenses   (139,235)   (16,127)   (3,912)   (8,625)   (167,899)   958    (166,941)
External administrative expenses   (56,792)   (87,774)   (146,958)   (170,501)   (462,025)   —      (462,025)
Inter-segment administrative expenses   (3,190)   (5,535)   —      —      (8,725)   8,725    —   
Corporate expenses   (50,765)   (49,907)   (8,216)   (5,185)   (114,073)   (14,365)   (128,438)
Segment administrative expenses   (110,747)   (143,216)   (155,174)   (175,686)   (584,823)   (5,640)   (590,463)
Impairment losses on trade receivables   (1,681)   (10,787)   (14,058)   (2,298)   (28,824)   (1)   (28,825)
Other income   2,051    4,990    6,665    18,526    32,232    4    32,236 
Inter-segment other income   9,264    708    —      —      9,972    (9,972)   —   
Other income   11,315    5,698    6,665    18,526    42,204    (9,968)   32,236 
Segment operating profit (loss)   162,972    81,215    112,561    147,566    504,314    (23,165)   481,149 
Share of profit of equity accounted investees, net of taxes   2,710    —      5,363    —      8,073    —      8,073 
Exchange difference, net   445    3,549    58,172    21,756    83,922    61,280    145,202 
Interest expense, net   (13,865)   (30,833)   (70,923)   (127,920)   (243,541)   (100,335)   (343,876)
Segment profit (loss) before tax   152,262    53,931    105,173    41,402    352,768    (62,220)   290,548 
Other disclosures                                   
Depreciation and amortization   (26,512)   (35,969)   (30,571)   (64,831)   (157,883)   (8,115)   (165,998)
Capital expenditure   (16,236)   (28,382)   (12,934)   (36,357)   (93,909)   (7,382)   (101,291)
Segment assets   2,400,793    1,089,598    2,415,418    3,168,617    9,074,426    (1,792,404)   7,282,022 
Segment liabilities   1,151,687    687,104    1,335,685    1,925,403    5,099,879    366,946    5,466,825 

 

9 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2026

 

(i)Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Peru S.A.C. remains.

 

10 

Filing Exhibits & Attachments

2 documents

Keep reading